Skip to content
10-Q

Quarterly Report

Citius Pharmaceuticals, Inc. CTXR

0001213900-26-015878

← back to feed
Filed
Feb 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Feb 10, 2026 22.38M sh
Shares Diluted Q1 2026 · Dec 31, 2025 21.5M sh
Shares Diluted Q1 2026 · Dec 31, 2024 7.49M sh
Operating Cash Flow Q1 2026 · Dec 31, 2025 −$13.01M
Operating Cash Flow Q1 2026 · Dec 31, 2024 −$4.73M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $7.72M
Cash And Equivalents Q1 2026 · Sep 30, 2025 $4.25M
Stockholders Equity Q1 2026 · Dec 31, 2025 $79.96M
Stockholders Equity Q1 2026 · Sep 30, 2025 $67.55M
Current Liabilities Q1 2026 · Dec 31, 2025 $38.21M
Current Liabilities Q1 2026 · Sep 30, 2025 $44.91M
Total Liabilities Q1 2026 · Dec 31, 2025 $46.92M
Total Liabilities Q1 2026 · Sep 30, 2025 $53.41M
Current Assets Q1 2026 · Dec 31, 2025 $37.95M
Current Assets Q1 2026 · Sep 30, 2025 $27.93M
Total Assets Q1 2026 · Dec 31, 2025 $140.39M
Total Assets Q1 2026 · Sep 30, 2025 $130.94M
Eps Diluted Q1 2026 · Dec 31, 2025 −$0.38
Eps Diluted Q1 2026 · Dec 31, 2024 −$1.30
Eps Basic Q1 2026 · Dec 31, 2025 −$0.38
Eps Basic Q1 2026 · Dec 31, 2024 −$1.30
Sga Expense Q1 2026 · Dec 31, 2025 $5.72M
Sga Expense Q1 2026 · Dec 31, 2024 $5.39M
Rd Expense Q1 2026 · Dec 31, 2025 $1.6M
Rd Expense Q1 2026 · Dec 31, 2024 $2.13M
Operating Income Q1 2026 · Dec 31, 2025 −$9.02M
Operating Income Q1 2026 · Dec 31, 2024 −$10.04M
Gross Profit Q1 2026 · Dec 31, 2025 $3.15M
Cost Of Revenue Q1 2026 · Dec 31, 2025 $789.21K
Revenue Q1 2026 · Dec 31, 2025 $3.94M